Sight Sciences (SGHT) Projected to Post Quarterly Earnings on Wednesday

Sight Sciences (NASDAQ:SGHT) is expected to post its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect Sight Sciences to announce earnings of ($0.15) per share and revenue of $21.6940 million for the quarter. Parties can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

Sight Sciences (NASDAQ:SGHT) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.05). Sight Sciences had a negative net margin of 46.83% and a negative return on equity of 52.34%. The business had revenue of $19.70 million during the quarter, compared to the consensus estimate of $18.46 million. On average, analysts expect Sight Sciences to post $-1 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Sight Sciences Stock Performance

Shares of SGHT traded up $0.09 during mid-day trading on Wednesday, hitting $5.38. The company’s stock had a trading volume of 6,879 shares, compared to its average volume of 265,464. The stock’s 50-day moving average is $5.09 and its two-hundred day moving average is $4.97. The firm has a market capitalization of $293.00 million, a PE ratio of -7.58 and a beta of 2.38. The company has a debt-to-equity ratio of 0.68, a quick ratio of 5.48 and a current ratio of 5.86. Sight Sciences has a one year low of $3.11 and a one year high of $9.24.

Analyst Ratings Changes

Several equities analysts recently commented on SGHT shares. Weiss Ratings cut shares of Sight Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, May 11th. UBS Group started coverage on shares of Sight Sciences in a research report on Tuesday. They issued a “buy” rating and a $7.00 price target on the stock. Finally, Citigroup boosted their price objective on shares of Sight Sciences from $5.15 to $6.00 and gave the stock a “neutral” rating in a report on Wednesday, July 8th. Five equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Sight Sciences has an average rating of “Hold” and a consensus price target of $7.75.

Insider Transactions at Sight Sciences

In other news, CFO James Rodberg sold 6,902 shares of Sight Sciences stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $5.36, for a total transaction of $36,994.72. Following the sale, the chief financial officer owned 224,037 shares of the company’s stock, valued at approximately $1,200,838.32. This trade represents a 2.99% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Paul Badawi sold 28,684 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $5.42, for a total value of $155,467.28. Following the sale, the chief executive officer owned 6,122,472 shares in the company, valued at approximately $33,183,798.24. This represents a 0.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 58,566 shares of company stock worth $318,827 over the last 90 days. Insiders own 30.40% of the company’s stock.

Hedge Funds Weigh In On Sight Sciences

Hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. lifted its holdings in shares of Sight Sciences by 5.7% during the 3rd quarter. Vanguard Group Inc. now owns 1,906,696 shares of the company’s stock worth $6,559,000 after acquiring an additional 102,609 shares during the period. Geode Capital Management LLC raised its position in Sight Sciences by 3.3% in the fourth quarter. Geode Capital Management LLC now owns 880,958 shares of the company’s stock worth $6,988,000 after purchasing an additional 27,802 shares in the last quarter. State Street Corp raised its position in Sight Sciences by 11.0% in the fourth quarter. State Street Corp now owns 737,359 shares of the company’s stock worth $5,847,000 after purchasing an additional 73,362 shares in the last quarter. Integral Health Asset Management LLC bought a new position in Sight Sciences during the fourth quarter worth about $3,370,000. Finally, Invesco Ltd. bought a new position in Sight Sciences during the fourth quarter worth about $2,791,000. Institutional investors and hedge funds own 55.51% of the company’s stock.

Sight Sciences Company Profile

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.